+

WO2002002050A3 - Prevention and treatment of mycoplasma-associated diseases - Google Patents

Prevention and treatment of mycoplasma-associated diseases Download PDF

Info

Publication number
WO2002002050A3
WO2002002050A3 PCT/BR2001/000083 BR0100083W WO0202050A3 WO 2002002050 A3 WO2002002050 A3 WO 2002002050A3 BR 0100083 W BR0100083 W BR 0100083W WO 0202050 A3 WO0202050 A3 WO 0202050A3
Authority
WO
WIPO (PCT)
Prior art keywords
mycoplasma
prevention
treatment
associated diseases
cell proliferation
Prior art date
Application number
PCT/BR2001/000083
Other languages
French (fr)
Other versions
WO2002002050A2 (en
Inventor
Maria De Lourdes Higuchi
Sergio Schenkman
Original Assignee
Maria De Lourdes Higuchi
Sergio Schenkman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maria De Lourdes Higuchi, Sergio Schenkman filed Critical Maria De Lourdes Higuchi
Priority to DE60135843T priority Critical patent/DE60135843D1/en
Priority to AU2001267165A priority patent/AU2001267165A1/en
Priority to EP01944764A priority patent/EP1296554B1/en
Priority to CA2383850A priority patent/CA2383850C/en
Publication of WO2002002050A2 publication Critical patent/WO2002002050A2/en
Priority to US10/086,913 priority patent/US7108851B2/en
Publication of WO2002002050A3 publication Critical patent/WO2002002050A3/en
Priority to US10/952,003 priority patent/US7335638B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to the prevention and treatment of diseases associated with undesirable cell proliferation, including atherosclerotic narrowing of blood vessels and malignancy, comprising preventing or treating infection by mycoplasma. It is based, at least in part, on the discovery that, in many cases, mycoplasma infection exists coincident with undesirable cell proliferation and/or proliferation of other infectious organisms.
PCT/BR2001/000083 2000-07-03 2001-07-03 Prevention and treatment of mycoplasma-associated diseases WO2002002050A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE60135843T DE60135843D1 (en) 2000-07-03 2001-07-03 PREVENTION AND TREATMENT OF MYCOPLASMA ASSOCIATED DISEASES WITH TRANS-SIALIDASE AND / OR NEURAMINIDASE
AU2001267165A AU2001267165A1 (en) 2000-07-03 2001-07-03 Prevention and treatment of mycoplasma-associated diseases
EP01944764A EP1296554B1 (en) 2000-07-03 2001-07-03 Prevention and treatment of mycoplasma-associated diseases using trans-sialidase and/or neuraminidase
CA2383850A CA2383850C (en) 2000-07-03 2001-07-03 Prevention and treatment of mycoplasma-associated diseases
US10/086,913 US7108851B2 (en) 2000-07-03 2002-03-01 Prevention and treatment of mycoplasma-associated diseases
US10/952,003 US7335638B2 (en) 2000-07-03 2004-09-28 Prevention and treatment of mycoplasma-associated diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR0002989-0A BR0002989A (en) 2000-07-03 2000-07-03 Anti-mycoplasma medication and its associations with other infectious agents
BRPI0002989-0 2000-07-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/086,913 Continuation US7108851B2 (en) 2000-07-03 2002-03-01 Prevention and treatment of mycoplasma-associated diseases

Publications (2)

Publication Number Publication Date
WO2002002050A2 WO2002002050A2 (en) 2002-01-10
WO2002002050A3 true WO2002002050A3 (en) 2002-08-15

Family

ID=3944635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2001/000083 WO2002002050A2 (en) 2000-07-03 2001-07-03 Prevention and treatment of mycoplasma-associated diseases

Country Status (3)

Country Link
AU (1) AU2001267165A1 (en)
BR (1) BR0002989A (en)
WO (1) WO2002002050A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003213898A1 (en) * 2002-03-28 2003-10-13 Maria De Lourdes Higuchi Prevention and treatment of mycoplasma-associated diseases
US7674832B2 (en) 2003-03-28 2010-03-09 Higuchi Maria De Lourdes Compositions for promoting wound healing and treating psoriasis
US8822232B2 (en) 2003-03-28 2014-09-02 Maria De Lourdes Higuchi Diagnosis, prevention and treatment of disorders characterized by undesirable cell proliferation
BRPI1004987A2 (en) 2010-11-26 2013-03-26 Maria De Lourdes Higuchi prevention and treatment of mycoplasma-associated diseases
US7732410B2 (en) 2003-03-28 2010-06-08 Higuchi Maria De Lourdes Compositions for inhibiting atherosclerosis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BASEMAN ET AL.: "Sialic acid residues mediate mycoplasma pneumoniae attachment to human and sheep erythrocytes", INFECTION AND IMMUNITY, vol. 38, no. 1, October 1982 (1982-10-01), pages 389 - 391, XP002950818 *
NEYROLLES ET AL.: "Identification of two glycosylated components of mycoplasma penetrans: a surface-exposed capsular polysaccharide and a glycolipid fraction", MICROBIOLOGY, vol. 144, May 1998 (1998-05-01), pages 1247 - 1255, XP002950817 *
ROBERTS ET AL.: "Sialic acid-dependent adhesion of mycoplasma pneumoniae to purified glycoproteins", J. BIOL. CHEM., vol. 264, no. 16, 5 June 1989 (1989-06-05), pages 9289 - 9293, XP002950819 *
See also references of EP1296554A4 *

Also Published As

Publication number Publication date
BR0002989A (en) 2002-02-13
AU2001267165A1 (en) 2002-01-14
WO2002002050A2 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
WO2004014312A3 (en) Small-mer compositions and methods of use
WO2006033995A3 (en) Thiazolidin-4-ones having anti-hepatitis b activity
WO1999052515A3 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections
BR9913935A (en) Methods of treatment and prevention of infection caused by at least one virus of the family of flaviviridae and disease associated with said infection in a living host
EP1478322A4 (en) Beta-2'-OR 3'-HALONUCLEOSIDES
WO2002000242A8 (en) Human papilloma virus treatment
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2001036486A3 (en) Scfv antibodies against disease associated molecules
CA2400801A1 (en) Treatment of congestive heart failure by pretreated autologous blood
WO2005039630A3 (en) Immunogenic compositions
GB9902555D0 (en) Medicament
WO2000058475A3 (en) Streptococcus pneumoniae antigens
EP1296554A4 (en) Prevention and treatment of mycoplasma-associated diseases
WO2003049804A3 (en) Treatment of genitourinary tract disorders
WO2002002050A3 (en) Prevention and treatment of mycoplasma-associated diseases
WO2003063725A3 (en) Methods of preventing and treating flavivirus infection in animals
WO2003049674A3 (en) Method for treatment of enveloped viruses using jojoba oil esters
WO2001040473A3 (en) Pseudomonas aeruginosa antigens
WO2003087325A3 (en) Methods and compositions for preventing and treating microbial infections
WO2003018606A3 (en) Casein derived peptides and uses thereof in therapy
BRPI0516209A (en) prevention and treatment of mycoplasma-associated diseases
ZA200209632B (en) Methods for prevention of ulcers and improving physiological performance.
WO2002024887A3 (en) Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
MXPA03000033A (en) Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies.
WO2001087229A3 (en) Treating infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2383850

Country of ref document: CA

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001944764

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001944764

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001944764

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载